To assess safety of SB-656933 following repeat dosing for 14 days.
A randomised, double-blind, placebo controlled, dose ascending, parallel group study to evaluate the safety, tolerability, steady state pharmacokinetics and pharmacodynamics of SB-656933-AAA following repeated doses in healthy adult subjects. The pharmacokinetic interaction between repeated doses of SB-656933-AAA and single dose of simvastatin will also be assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Enrollment
36
The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
SB-656933-AAA matching placebo tablets will be administered orally.
Simvastatin will be provided as a 40 mg tablet.
GSK Investigational Site
London, United Kingdom
Assess safety of SB-656933 after repeat doses.
Time frame: after repeat doses
Investigate concentrations of SB-656933 in the body and how long it remains in the body over 14 days of repeat dosing.
Time frame: 14 days of repeat dosing.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.